Cartesian Therapeutics (NASDAQ:RNAC) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Cartesian Therapeutics (NASDAQ:RNACFree Report) in a report released on Monday morning, Benzinga reports. HC Wainwright currently has a $54.00 target price on the stock.

A number of other equities analysts also recently weighed in on the company. Leerink Partnrs reiterated an outperform rating on shares of Cartesian Therapeutics in a report on Tuesday, April 23rd. SVB Leerink started coverage on shares of Cartesian Therapeutics in a research note on Tuesday, April 23rd. They issued an outperform rating and a $39.00 price objective on the stock. Mizuho began coverage on shares of Cartesian Therapeutics in a research note on Friday, May 24th. They set a buy rating and a $40.00 target price for the company. Oppenheimer restated an outperform rating and set a $50.00 price target on shares of Cartesian Therapeutics in a report on Friday, June 14th. Finally, Needham & Company LLC reiterated a buy rating and set a $42.00 price objective on shares of Cartesian Therapeutics in a report on Wednesday, May 8th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of Buy and a consensus price target of $45.00.

Read Our Latest Stock Report on Cartesian Therapeutics

Cartesian Therapeutics Price Performance

Shares of NASDAQ:RNAC opened at $22.89 on Monday. The company’s fifty day moving average is $25.25 and its two-hundred day moving average is $22.36. Cartesian Therapeutics has a 12-month low of $11.66 and a 12-month high of $42.60.

Cartesian Therapeutics (NASDAQ:RNACGet Free Report) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($1.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.81) by ($1.16). The business had revenue of $5.84 million for the quarter. Cartesian Therapeutics had a negative net margin of 983.93% and a negative return on equity of 58.21%. On average, equities research analysts forecast that Cartesian Therapeutics will post 2.28 EPS for the current fiscal year.

Institutional Trading of Cartesian Therapeutics

Large investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC acquired a new stake in shares of Cartesian Therapeutics in the 1st quarter valued at $31,000. Hall Laurie J Trustee bought a new position in Cartesian Therapeutics during the first quarter valued at about $34,000. American International Group Inc. acquired a new stake in shares of Cartesian Therapeutics in the first quarter worth about $37,000. BNP Paribas Financial Markets bought a new stake in shares of Cartesian Therapeutics during the 1st quarter worth about $38,000. Finally, Delphi Financial Group Inc. acquired a new position in shares of Cartesian Therapeutics during the 1st quarter valued at about $430,000. 86.95% of the stock is owned by institutional investors.

About Cartesian Therapeutics

(Get Free Report)

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.

Featured Stories

Analyst Recommendations for Cartesian Therapeutics (NASDAQ:RNAC)

Receive News & Ratings for Cartesian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cartesian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.